By 2026, biomedical intellectual property RWA has become the brightest star in the RWA track. Behind it are three driving forces: clear policy support, mature technological foundation, and continuous funding. All of this is rewriting the financing landscape of the biomedical industry.

Ultimately, where is the problem? The biomedical industry requires huge investments. Developing an innovative drug from research to market can take over 10 years, with over 1 billion USD invested. Companies need financing, either by diluting equity or through bank loans, both of which are difficult and risky. Long financing cycles and high thresholds especially trap small and medium-sized pharmaceutical companies.

For investors, the biomedical sector is a cake they see but cannot eat. Participating in equity investment? It requires starting with several million USD, which ordinary people have no chance of accessing. Not to mention the professional issues like assessing drug development progress, clinical trial results, and patent value—these are too high a threshold. The most critical issue is liquidity—once money is invested, it’s not easy to exit.

Tokenization has changed all this. Patents for innovative drugs and intellectual property rights for medical equipment are tokenized, opening a new financing window for pharmaceutical companies that does not dilute equity, and allowing ordinary investors to participate in the profit sharing of this high-growth, high-barrier industry for the first time.

This is why the joint launch of the biomedical intellectual property RWA investment plan by USD1 stablecoin and ListaDAO is so significant. The minimum investment is as low as 100 USD1, with an annualized return stable between 8% and 12%. More importantly, there is a strict asset screening and risk management system backing it up. For the wealth management market, this is indeed a new option.